(Q39049796)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301680%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301680%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301680%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Enrico Amico

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301680%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Sergio Fucile

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301680%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Ferdinando Squitieri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301680%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Vittorio Maglione

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301680%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Mariagrazia Favellato

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301680%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Roberta Castrataro

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301680%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

2 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301680%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

published in

Human Molecular Genetics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301680%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301680%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301680%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

2251-2265

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24301680%20AND%20SRC:MED&resulttype=core&format=json

Huntington's disease: clinical presentation and treatment

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Impaired ganglioside metabolism in Huntington's disease and neuroprotective role of GM1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Drugs in development for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Exogenous and intracellularly generated sphingosine 1-phosphate can regulate cellular processes by divergent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Central nervous system-directed effects of FTY720 (fingolimod).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Fingolimod protects cultured cortical neurons against excitotoxic death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

FTY720, sphingosine 1-phosphate receptor modulator, selectively radioprotects hippocampal neural stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Cross-talk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Akt is altered in an animal model of Huntington's disease and in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Mutant huntingtin alters cell fate in response to microtubule depolymerization via the GEF-H1-RhoA-ERK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Protein aggregates in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Kinase inhibitors modulate huntingtin cell localization and toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: comparison with memantine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

A novel target for Huntington's disease: ERK at the crossroads of signaling. The ERK signaling pathway is implicated in Huntington's disease and its upregulation ameliorates pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Myelin-associated glycoprotein protects neurons from excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Axonal protective effects of the myelin-associated glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

AKT and CDK5/p35 mediate brain-derived neurotrophic factor induction of DARPP-32 in medium size spiny neurons in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Levels of BDNF impact oligodendrocyte lineage cells following a cuprizone lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Serine phosphorylation suppresses huntingtin amyloid accumulation by altering protein aggregation properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615

Early tolerability and safety of fingolimod in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDT615